Case Report

Hypochondroplasia in a Child with 1620C>G (Asn540Lys) Mutation in FGFR3


  • Hüseyin Anıl Korkmaz
  • Filiz Hazan
  • Ceyhun Dizdarer
  • Ajlan Tükün

Received Date: 04.08.2012 Accepted Date: 27.09.2012 J Clin Res Pediatr Endocrinol 2012;4(4):220-222 PMID: 23149434

Hypochondroplasia (HCP) is an autosomal dominant skeletal dysplasia characterized by short extremities, short stature and lumbar lordosis, usually exhibiting a phenotype similar to but milder than achondroplasia (ACP). Fibroblast growth factor receptor 3 gene (FGFR3) mutations in the germline are well-known causes of skeletal syndromes. FGFR3 is a negative regulator of bone growth and all mutations in FGFR3 are gain-of-function mutations that lead to skeletal dysplasias. We report a child who presented with short stature, a relatively long trunk, short legs, short arm span, radiographic evidence of HCP and mild mental retardation. Genetic analysis revealed a heterozygous 1620C>G (Asn540Lys) mutation in FGFR3. To our knowledge, ours is the first case report of HCP with a heterozygous 1620C>G (Asn540Lys) mutation in Turkey.

Keywords: Hypochondroplasia,fibroblast growth factor receptor 3,short stature


Hypochondroplasia (HCP) and achondroplasia (ACP) are two common skeletal disorders caused by heterozygous mutations in the fibroblast growth factor receptor 3 gene (FGFR3) (1,2). FGFR3 is located on chromosome 4 (4p16.3) and is composed of 19 exons and 18 introns (3). All of the mutations are inherited in a dominant pattern. Two mutations (1620C>A and 1620C>G) account for50-70% of all cases with HCP (4). Herein, we present a patient with HCP.

Case Report

A 4 8/12 years old female patient presented to our clinic with short stature. She was the second child of a 24-year-old mother and her 28-year-old husband. She was born full-term by normal vaginal delivery following an uncomplicated pregnancy. Her birth weight was 3050 g and her birth length was 46 cm.

At presentation, the patient’s anthropometric measurements revealed a height of 97 cm [-2.18 standard deviation score (SDS)] and a head circumference of 54 cm (+3.71 SDS); head circumference SDS-height SDS (DHc/Ht) SDS=+5.89. Physical examination showed skeletal disproportion with short limbs and a relatively long trunk [upper to lower segment ratio: 1.21 (>2 SDS)], brachydactyly, metaphyseal flaring, limitation of elbow extension, short legs [sitting height/height ratio: 0.6 (>2.5 SDS)] and a short arm span (10 cm shorter than her total height) (Figure 1). Her mother’s and father’s height were 154 and 172 cm, respectively, and target height was calculated as 156.5 cm. The patient’s developmental milestones were normal, but she had mild mental retardation. Neuropsychological evaluation (Bayley) revealed a developmental index of 60, a value below normal. She showed difficulties especially in language skills. Radiographic examination revealed characteristic features of HCP including a fibula longer than the tibia, square iliae and short femoral necks, a shortening of the pedicles of the vertebrae, with a narrowing of interpedicular distances. The large tubular bones were short and squat, with small epiphyses. The tubular hand bones were also slightly short. Muscle tone was normal, but motion range in many large and small joints was slightly increased. Bone age was 4 years. The karyotype was 46,XX.

We isolated genomic DNA from blood lymphocytes of the patient by standard procedures. Four coding exons (9, 10, 13, and 15) of FGFR3 were amplified using methods described previously (5). The polymerase chain reaction products were purified and sequenced on an ABI PRISM 3130 automated DNA sequencer (Applied Biosystems). A heterozygous 1620C>G (Asn540Lys) mutation was detected in exon 13.


HCP is an autosomal dominant skeletal disorder, and mutations in FGFR3 are present in most patients (3). In patients with HCP, the skeletal features are less severe than in patients with ACP (1,2). Therefore, the diagnosis of HCP is often difficult, and some affected patients may be evaluated as idiopathic short stature. Our patient presented with short stature (A and 1620C>G mutations which lead to Asn540Lys aminoacid substitution are detected in approximately 50-70% of affected individuals (4). Codon 540 in exon 13 is a major hotspot (7). The other mutations of this gene account for fewer than 2% of HCP patients (8). However, familial cases who were not linked to FGFR3 have been reported that support a genetically heterogeneous condition (9,10). FGFR3 is a negative regulator of bone growth and all mutations of FGFR3 are gain-of-function mutations that lead to skeletal dysplasias (11,12). The phenotype of HCP is similar, but milder compared to ACP. Therefore, HCP is rarely recognized before the age of 3 years (6). In our patient, a diagnosis of HCP was suspected at age of 4 8/12 years. Skeletal features are reported to be more severe in HCP patients with Asn540Lys mutations than in HCP patients without the FGFR3 Asn540Lys mutation (6).

N540K mutations in the FGFR3 cause the most severe forms of sporadic HCP (10). In patients with N540K mutations, adult height ranges from 138 cm to 155 cm in men and from 128 cm to 145 cm in women (13,14). The use of recombinant growth hormone (rGH) therapy for HCP has been evaluated by several centers in trials (2,14,15,16,17,18). In most of these trials, a statistically significant increase in predicted growth rate was reported. However, there was also a concern that rGH might aggravate body disproportion, a question that remains under debate (2,17). Thus, rGH therapy for HCP is still considered experimental and controversial (6). The only possible alternative to rGH treatment is a limb-lengthening procedure. Although the complication rate of this procedure was initially high, outcomes have steadily improved, and significant increases in overall height up to 7-12 cm have been reported (19). However, this procedure is invasive and entails disability and discomfort (6). We decided that our patient would receive rGH therapy.

It has been estimated that 10 to 20% of cases of HCP had mild mental handicap (20). Recently, mental retardation has been reported in a HCP patient with Asn540Lys mutation in FGFR3 gene (21). The patient presented in this report is another example of mental retardation occurring as a clinical consequence of Asn540Lys mutation.

In summary, mutation screening is appropriate when the clinical and radiological features of a patient reveal findings suggestive of a skeletal dysplasia. The presence of FGFR3 mutations dominates the clinical picture and its identification is important not only for genetic counseling and recurrence risk but also to provide information on perinatal lethality, severity of the dysplasia and prognosis. A coordinated collaboration between gynecologists, pediatricians and geneticists is needed for the evaluation of such patients.

1. Hall BD, Spranger J. Hypochondroplasia: clinical and radiological aspects in 39 cases. Radiology 1979;133:95-100.
2. Matsui Y, Yasui N, Kimura T, Tsumaki N, Kawabata H, Ochi T. Genotype phenotype correlation in achondroplasia and hypochondroplasia. J Bone Joint Surg Br 1998;80:1052-1056.
3. Keegan K, Rooke L, Hayman M, Spurr NK. The fibroblast growth factor receptor 3 gene (FGFR3) is assigned to human chromosome 4. Cytogenet Cell Genet 1993;62:172-175.
4. Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA. Distinct missense mutation of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000;67:1411-1421. Epub 2000 Oct 27
5. Mortier G, Nuytinck L, Craen M, Renard JP, Leroy JG, de Paepe A. Clinical and radiographic features of a family withhypochondroplasia owing to a novel Asn540Ser mutation inthe fibroblastgrowth factor receptor 3 gene. J Med Genet 2000;37:220-224.
6. Francomano CA. Hypochondroplasia. GeneReviews Source: University of Washington, Seattle; 2005.
7. Bellus GA, McIntosh I, Szabo J, Aylsworth A, Kaitila I, Francomano CA. Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene. Ann N Y Acad Sci 1996;785:182-187.
8. Castro-Feijóo L, Loidi L, Vidal A, Parajes S, Rosón E, Alvarez A, Cabanas P, Barreiro J, Alonso A, Domínguez F, Pombo M. Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene? Eur J Endocrinol 2008;159:243-249. Epub 2008 Jun 26
9. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasia, Muenke craniosynostosis and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000;21:23-39. 
10. Rousseau F, Bonaventure J, Legeai-Mallet L, Schmidt H, Weissenbach J, Maroteaux P, Munnich A, Le Merrer M. Clinical and genetic heterogeneity of hypochondroplasia. J Med Genet 1996;33:749-752.
11. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996;84:911-921.
12. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 1999;64:722-731.
13. Maroteaux P, Falzon P. [Hypochondroplasia: review of 80 cases]. Arch Fr Pediatr 1988;45:105-109.
14. Bridges NA, Hindmarsh PC, Brook CG. Growth of children with hypochondroplasia treated with growth hormone for up to three years. Horm Res 1991;36:56-60.
15. Burren CP, Werther GA. Skeletal dysplasias: response to growth hormone therapy. J Pediatr Endocrinol Metab 1996;9:31-40.
16. Ramaswami U, Hindmarsh PC, Brook CGD. Growth hormone therapy in hypochondroplasia. Acta Paediatr 1999;88:116-117.
17. Hagenas L, Hertel T. Skeletal dysplasia, growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short children. Horm Res 2003;60:65-70.
18. Rothenbuhler A, Linglart A, Piquard C, Bougnères P. A pilot study of discontinuous, insulin-like growth factor 1-dosing growth hormone treatment in young children with FGFR3 N540K-mutated hypochondroplasia. J Pediatr 2012;160:849-853. Epub 2011 Dec 2
19. Yasui N, Kawabata H, Kojimoto H, Ohno H, Matsuda S, Araki N, Shimomura Y, Ochi T. Lengthening of the lower limbs in patients with achondroplasia and hypochondroplasia. Clin Orthop Relat Res 1997;344:298-306.
20. Wynne-Davies R, Patton MA. The frequency of mental retardation in hypochondroplasia. J Med Genet 1991;28:644.
21. Rodríguez Delgado J, Guerrero Fernández J, Gracia Bouthelier R. Hypochondroplasia and mental retardation. An Pediatr Barc) 2008;68:629-632.